TW202245777A - Parp7抑制劑之給藥方案 - Google Patents

Parp7抑制劑之給藥方案 Download PDF

Info

Publication number
TW202245777A
TW202245777A TW111105389A TW111105389A TW202245777A TW 202245777 A TW202245777 A TW 202245777A TW 111105389 A TW111105389 A TW 111105389A TW 111105389 A TW111105389 A TW 111105389A TW 202245777 A TW202245777 A TW 202245777A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
cancer
Prior art date
Application number
TW111105389A
Other languages
English (en)
Chinese (zh)
Inventor
梅麗莎 瑪麗 瓦斯賓達
路卡斯 Ｊ 奧特利
薇薇安納 波茲翁
凱文 韋恩 坎茲
蘇達 帕拉蘇拉曼
威廉 麥寇羅奇
諾蘭 伍德
Original Assignee
美商律幫治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商律幫治療股份有限公司 filed Critical 美商律幫治療股份有限公司
Publication of TW202245777A publication Critical patent/TW202245777A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111105389A 2021-02-16 2022-02-15 Parp7抑制劑之給藥方案 TW202245777A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163149901P 2021-02-16 2021-02-16
US63/149,901 2021-02-16
US202163275163P 2021-11-03 2021-11-03
US63/275,163 2021-11-03

Publications (1)

Publication Number Publication Date
TW202245777A true TW202245777A (zh) 2022-12-01

Family

ID=80449181

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105389A TW202245777A (zh) 2021-02-16 2022-02-15 Parp7抑制劑之給藥方案

Country Status (6)

Country Link
US (3) US20220265654A1 (https=)
EP (1) EP4294399A1 (https=)
JP (1) JP2024506684A (https=)
KR (1) KR20230146593A (https=)
TW (1) TW202245777A (https=)
WO (1) WO2022177877A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI858843B (zh) * 2022-08-09 2024-10-11 大陸商成都百裕製藥股份有限公司 哌類化合物和ｐｄ－１抑制劑或ｐｄ－ｌ１抑制劑的組合物以及其在製備抗腫瘤藥物中的用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7273791B2 (ja) * 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI858843B (zh) * 2022-08-09 2024-10-11 大陸商成都百裕製藥股份有限公司 哌類化合物和ｐｄ－１抑制劑或ｐｄ－ｌ１抑制劑的組合物以及其在製備抗腫瘤藥物中的用途

Also Published As

Publication number Publication date
US20240325391A1 (en) 2024-10-03
JP2024506684A (ja) 2024-02-14
US20250064803A1 (en) 2025-02-27
EP4294399A1 (en) 2023-12-27
WO2022177877A1 (en) 2022-08-25
KR20230146593A (ko) 2023-10-19
US20220265654A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
AU2022241509B2 (en) Treatment of HER2 positive cancers
US20240325391A1 (en) Dosage regimens for parp7 inhibitors
US20220387618A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
JP7579781B2 (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
TW201534305A (zh) 使用組合療法治療癌症之方法
IL303502A (en) Combination therapies for treatment of her2 cancer
JP2019526613A (ja) 癌のための併用療法
JP2024012649A (ja) Ｃｈｋ１阻害剤を含む癌の治療方法
US20220125777A1 (en) Combination of a cdk inhibitor and a pim inhibitor
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
CN116568306A (zh) 用于治疗实体瘤的包含krasg12c抑制剂和egfr抑制剂的方法和组合物
US20240058339A1 (en) Combination therapy for cancers with kras mutation
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
CN117177753A (zh) Parp7抑制剂的剂量方案
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
RU2858208C2 (ru) Применение соединения гетероарилоксинафталина
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate